Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. adiras

ADiRaS

Alzheimer’s Disease Diagnosis by Spectroscopy. Accurate and Non-Invasive Medical Device for the Diagnosis of Early Stage Alzheimer's Disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ADiRaS project word cloud

Explore the words cloud of the ADiRaS project. It provides you a very rough idea of what is the project "ADiRaS" about.

expensive    rs    earlier    healthcare    performing    living    raman    analyzes    treatment    fluid    blood    price    people    institutionalization    solution    first    allergic    received    bleeding    proper    expert    ameliorating    8bn    time    population    suffer    techniques    headaches    saving    consists    aging    affordable    diagnose    procedure    plasma    puncture    ad    invasive    screening    diagnosis    pet    lumbar    pain    absolutely    multiple    patient    admission    65    tomography    numbness    spectroscopy    nursery    quality    severe    1500    net    spinal    million    huge    improves    lacks    infections    revolutionary    emission    radioactive    ht    disease    medical    patients    400    relatively    onto    reference    marker    device    delaying    alzheimer    company    reactions    life    temporary    selling    legs    market    scans    brain    canal    symptoms    cerebrospinal    diagnostic    accurate    total    positron    2050    50    injected   

Project "ADiRaS" data sheet

The following table provides information about the project.

Coordinator		 RAMAN HEALTH TECHNOLOGIES SL 

Organization address
address: AVDA FRANCISCO VALLES 8 BIOINCUBADORA PARQUE TECNOLOGICO
city: BOECILLO VALLADOLID
postcode: 47151
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RAMAN HEALTH TECHNOLOGIES SL ES (BOECILLO VALLADOLID) coordinator 50˙000.00

Map

 Project objective

Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s brain after being injected with a radioactive marker (cost of €1500) which can cause major allergic reactions. The other method analyzes the cerebrospinal fluid, which requires performing the patient a lumbar puncture. This procedure (relatively expensive, €400) can cause severe headaches, temporary pain of numbness to legs, infections and bleeding into the spinal canal.

There are more than 30 million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lacks of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission.

Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer’s Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer’s Disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADIRAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADIRAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More